MedTrace Logo

A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer

NCT02141659 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2018-11-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the tolerability and safety of TAK-385 in hormone treatment-naïve participants with non-metastatic prostate cancer.

Conditions

  • Hormone Treatment-naïve Participants With Prostate Cancer

Interventions

DRUG

TAK-385

TAK-385 Tablets.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-01
Primary Completion
2017-04-20
Completion
2017-04-20

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02141659 on ClinicalTrials.gov